ICL to Acquire Evogene's Subsidiary Lavie Bio, Revolutionizing Ag-Biological Products

Evogene's Lavie Bio Acquisition by ICL expected to close in 2025, transferring key assets and advancing ag-biological products.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here